Reports Q3 revenue $5.29M, consensus $4.98M. Results were reported on Thursday. “The theme of my presentation at the Stifel Healthcare Conference earlier this week was ‘It’s Happening!’,” said Arun Menawat, Profound’s CEO and chairman. “As demonstrated by our strong revenue and TULSA Procedure volume growth, increased gross margin, improved bottom line, and rapidly expanding TULSA-PRO installed base, we were not only able to successfully navigate through an unusually challenging second quarter, but also delivered record results in Q3-2025. So far, that positive momentum has continued into the fourth quarter, and we look forward to updating investors as we progress.” This report corrects the consensus revenue estimate.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PROF:
- Profound Medical reports Q3 EPS (26c), consensus (38c)
- Profound Medical’s Earnings Call Highlights Growth and Challenges
- Profound Medical’s Financial Struggles: Can the Company Secure Funding to Avoid Liquidation?
- Profound Medical files $150M mixed securities shelf
- Profound Medical Achieves Record Revenue Growth in Q3 2025